Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Abstract
In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well tolerated and safe. Serum and brain creatine concentrations increased in the creatine-treated group and returned to baseline after washout. Serum 8-hydroxy-2'-deoxyguanosine (8OH2'dG) levels, an indicator of oxidative injury to DNA, were markedly elevated in HD and reduced by creatine treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Oral administration of creatine at a dose of 8 g/day for 16 weeks is well tolerated, safe and bioavailable to the brain, and it decreased serum 8-hydroxy-2-deoxyguanosine levels.
“We found that oral administration of creatine at a dose of 8 g/day for 16 weeks is well tolerated, safe and bioavailable to the brain, and it decreased serum 8-hydroxy-2-deoxyguanosine levels, a marker for oxidative stress.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [134]
Cites
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522 · see citing works
Self-citationIncreased oxidative damage to DNA in ALS patients
Bogdanov, M. B., Brown, R. H., Matson, W. R., Smart, R. J., Hayden, D. L., O’Donnell, H. C., Beal, M. F., & Cudkowicz, M. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00349-x · Cited by 334 · see citing works
Self-citationOxidative stress in patients with Friedreich ataxia
Schulz, J. B., Dehmer, T., Schöls, L. J., Mende, H. E., Hardt, C., Vorgerd, M., Bürk, K., Matson, W. R., DICHGANS, J., Beal, M. F., et al. (2000) · Neurology · doi:10.1212/wnl.55.11.1719 · Cited by 305 · see citing works
Self-citationAndreassen, O. A., Dedeoglu, A., Ferrante, R. J., Jenkins, B. G., Ferrante, K. L., Thomas, M., Friedlich, A., Browne, S. E., Schilling, G., Borchelt, D. R., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0406 · Cited by 293 · see citing works
Self-citationIncrease of total creatine in human brain after oral supplementation of creatine-monohydrate
Dechent, P., Pouwels, P. J. W., Wilken, B., Hanefeld, F., & Frahm, J. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r698 · Cited by 221 · see citing works
Bogdanov, M. B., Beal, M. F., McCabe, D. R., Griffin, R. M., & Matson, W. R. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00113-6 · Cited by 179 · see citing works
Self-citationDedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169 · see citing works
Self-citationCreatine supplementation in Huntington’s disease
Verbessem, P., Lemiere, J., Eijnde, B. O., Swinnen, S. P., Vanhees, L., Leemputte, M. V., Hespel, P., & Dom, R. (2003) · Neurology · doi:10.1212/01.wnl.0000090629.40891.4b · Cited by 163 · see citing works
Creatine therapy for Huntington’s disease: Clinical and MRS findings in a 1-year pilot study
Tabrizi, S. J., Blamire, A. M., Manners, D. N., Rajagopalan, B., Styles, P., Schapira, A. H. V., & Warner, T. T. (2003) · Neurology · doi:10.1212/01.wnl.0000070186.97463.a7 · Cited by 87 · see citing works
Jenkins, B. G., Brouillet, E., Chen, Y. I., Storey, E., Schulz, J. B., Kirschner, P. B., Beal, M. F., & Rosen, B. R. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199605000-00011 · Cited by 84 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Walker, F. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60111-1 · Cited by 2,623 · see citing works
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,751 · see citing works
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641 · see citing works
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016 · see citing works
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848 · see citing works
Chemical Basis of Reactive Oxygen Species Reactivity and Involvement in Neurodegenerative Diseases
Collin, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102407 · Cited by 822 · see citing works
Björkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., André, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C., Soulet, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080178 · Cited by 646 · see citing works
Tabrizi, S. J., Reilmann, R., Roos, R. A. C., Dürr, A., Leavitt, B. R., Owen, G. N., Jones, R., Johnson, H. J., Craufurd, D., Hicks, S. L., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70263-0 · Cited by 540 · see citing works
Schapira, A. H. V. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61305-6 · Cited by 499 · see citing works
Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases
Trushina, E. V., & McMurray, C. T. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.10.056 · Cited by 440 · see citing works
de Vries, H. E., Witte, M. E., Hondius, D., Rozemüller, A. J. M., Drukarch, B., Hoozemans, J. J. M., & van Horssen, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.001 · Cited by 432 · see citing works
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 416 · see citing works
Self-citationFunctions and effects of creatine in the central nervous system
Andres, R. H., Ducray, A., Schlattner, U., Wallimann, T., & Widmer, H. R. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.02.035 · Cited by 372 · see citing works
Beyond the brain: widespread pathology in Huntington's disease
van der Burg, J. M. M., Björkqvist, M., & Brundin, P. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70178-4 · Cited by 362 · see citing works
Creatine: Endogenous Metabolite, Dietary, and Therapeutic Supplement
Brosnan, J. T., & Brosnan, M. E. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093621 · Cited by 347 · see citing works
What Is Nuclear Factor Kappa B (NF-κB) Doing in and to the Mitochondrion?
Albensi, B. C. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00154 · Cited by 341 · see citing works
Oxidative Damage in Huntington's Disease Pathogenesis
Browne, S. E., & Beal, M. F. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.2061 · Cited by 309 · see citing works
Self-citationNetwork Organization of the Huntingtin Proteomic Interactome in Mammalian Brain
Shirasaki, D. I., Greiner, E. R., Al-Ramahi, I., Gray, M., Boontheung, P., Geschwind, D. H., Botas, J., Coppola, G., Horvath, S., Loo, J. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.024 · Cited by 297 · see citing works
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294 · see citing works
Self-citationSingh, S., Vrishni, S., Singh, B. K., Rahman, I., & Kakkar, P. (2010) · Free Radical Research · doi:10.3109/10715762.2010.507670 · Cited by 294 · see citing works
Mitochondria: A therapeutic target in neurodegeneration
Moreira, P. I., Zhu, X., Wang, X., Lee, H., Nunomura, A., Petersen, R. B., Perry, G. L., & Smith, M. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.007 · Cited by 286 · see citing works
Mitochondria in Huntington's disease
Damiano, M. G., Galvan, L., Déglon, N., & Brouillet, E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.012 · Cited by 282 · see citing works
Transcriptional signatures in Huntington's disease
Cha, J.-H. J. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.03.004 · Cited by 267 · see citing works
Impaired PGC-1α function in muscle in Huntington's disease
Chaturvedi, R. K., Adhihetty, P. J., Shukla, S., Hennessy, T., Calingasan, N. Y., Yang, L., Starkov, A. A., Kiaei, M., Cannella, M., Sassone, J., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp243 · Cited by 237 · see citing works
Self-citationOxidative Stress and Huntington’s Disease: The Good, the Bad, and the Ugly
Kumar, A., & Ratan, R. R. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160205 · Cited by 236 · see citing works
Yang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Beal, M. F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 232 · see citing works
Self-citationHuntington's Disease: Can Mice Lead the Way to Treatment?
Crook, Z. R., & Housman, D. E. (2011) · Neuron · doi:10.1016/j.neuron.2010.12.035 · Cited by 229 · see citing works
Chen, C., Wu, Y., Cheng, M., Liu, J., Lee, Y., Lee, P.-W., Soong, B., & Chiu, D. T.-Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.093 · Cited by 226 · see citing works
PGC-1α, mitochondrial dysfunction, and Huntington's disease
Johri, A., Chandra, A., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.016 · Cited by 223 · see citing works
Self-citationDalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Björkqvist, M., Petersén, Å., Jackson, G. S., Isaacs, J. D., Kristiansen, M., Bates, G. P., et al. (2007) · Journal of Proteome Research · doi:10.1021/pr0700753 · Cited by 223 · see citing works
Energy deficit in Huntington disease: why it matters
Mochel, F., & Haller, R. G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45691 · Cited by 220 · see citing works
Paulson, H. L. (2009) · Journal of Neuro-Ophthalmology · doi:10.1097/wno0b013e3181b416de · Cited by 220 · see citing works
Mitochondrial Creatine Kinase Activity Prevents Reactive Oxygen Species Generation
Meyer, L. E., Machado, L. B., Santiago, A. P. S. A., da‐Silva, W. S., Felice, F. G. D., Holub, O., de Oliveira, M. F., & Galina, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604123200 · Cited by 210 · see citing works
Synthesis and transport of creatine in the CNS: Importance for cerebral functions
Béard, E., & Braissant, O. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06935.x · Cited by 192 · see citing works
Neuroprotective effects of creatine
Beal, M. F. (2011) · Amino Acids · doi:10.1007/s00726-011-0851-0 · Cited by 191 · see citing works
Self-citationAdhihetty, P. J., & Beal, M. F. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8053-y · Cited by 184 · see citing works
Self-citationOxidative stress biomarkers in sporadic ALS
Mitsumoto, H., Santella, R. M., Liu, X., Bogdanov, M. B., Zipprich, J., Wu, H., Mahata, J., Kilty, M., Bednarz, K., Bell, D. A., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960801933942 · Cited by 180 · see citing works
Self-citationEvidence-based guideline: Pharmacologic treatment of chorea in Huntington disease [RETIRED]
Armstrong, M. J., & Miyasaki, J. M. (2012) · Neurology · doi:10.1212/wnl.0b013e318263c443 · Cited by 180 · see citing works
Antioxidant gene therapy against neuronal cell death
Navarro-Yepes, J., Zavala-Flores, L. M., Anandhan, A., Wang, F., Skotak, M., Chandra, N., Li, M., Pappa, A., Martínez‐Fong, D., Razo, L. M. D., et al. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.007 · Cited by 177 · see citing works
Machado–Joseph disease/spinocerebellar ataxia type 3
Paulson, H. L. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-51892-7.00027-9 · Cited by 175 · see citing works
Effects of Creatine Supplementation on Brain Function and Health
Forbes, S. C., Cordingley, D. M., Cornish, S. M., Gualano, B., Roschel, H., Ostojić, S. M., Rawson, E. S., Roy, B. D., Prokopidis, K., Giannos, P., et al. (2022) · Nutrients · doi:10.3390/nu14050921 · Cited by 174 · see citing works
Therapeutic interventions for symptomatic treatment in Huntington's disease
Mestre, T., Ferreira, J. J., Coelho, M. M., Rosa, M. M., & Sampaio, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006456.pub2 · Cited by 173 · see citing works
Stack, C., Ho, D. J., Wille, E. J., Calingasan, N. Y., Williams, C. R., Liby, K. T., Sporn, M. B., Dumont, M., & Beal, M. F. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.017 · Cited by 171 · see citing works
Self-citationCreatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub4 · Cited by 169 · see citing works
Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants
Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 167 · see citing works
Self-citationTherapeutic Advances for Huntington’s Disease
Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., & Kim, J.-J. (2020) · Brain Sciences · doi:10.3390/brainsci10010043 · Cited by 166 · see citing works
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research
Jiang, A., Handley, R. R., Lehnert, K., & Snell, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613021 · Cited by 168 · see citing works
Johri, A., Calingasan, N. Y., Hennessey, T., Sharma, A., Yang, L., Wille, E. J., Chandra, A., & Beal, M. F. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr541 · Cited by 161 · see citing works
Self-citationDevelopment of biomarkers for Huntington's disease
Weir, D. W., Sturrock, A., & Leavitt, B. R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70070-9 · Cited by 159 · see citing works
Antioxidants in Huntington's disease
Johri, A., & Beal, M. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.014 · Cited by 158 · see citing works
Self-citationExploring the therapeutic role of creatine supplementation
Gualano, B., Artioli, G. G., Poortmans, J. R., & Lancha Junior, A. H. (2010) · Amino Acids · doi:10.1007/s00726-009-0263-6 · Cited by 156 · see citing works
Politis, M., Lahiri, N., Niccolini, F., Su, P., Wu, K., Giannetti, P., Scahill, R. I., Turkheimer, F., Tabrizi, S. J., & Piccini, P. P. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.011 · Cited by 156 · see citing works
The Role of the Immune System in Huntington’s Disease
Ellrichmann, G., Reick, C., Saft, C., & Linker, R. A. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/541259 · Cited by 155 · see citing works
Kumar, A., & Singh, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00206 · Cited by 154 · see citing works
Mouse models of Huntington's disease and methodological considerations for therapeutic trials
Ferrante, R. J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.04.001 · Cited by 150 · see citing works
Self-citationMitoenergetic failure in Alzheimer disease
Parihar, M. S., & Brewer, G. J. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00232.2006 · Cited by 149 · see citing works
Spinocerebellar ataxias: an update
Soong, B., & Paulson, H. L. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3281fbd3dd · Cited by 148 · see citing works
Matos, C. A., de Almeida, L. P., & Nóbrega, C. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14541 · Cited by 145 · see citing works
† (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70262-5 · Cited by 144 · see citing works
Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities
Sbodio, J. I., Snyder, S. H., & Paul, B. D. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7321 · Cited by 143 · see citing works
Role of oxidative DNA damage in mitochondrial dysfunction and Huntington’s disease pathogenesis
Ayala‐Peña, S. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.017 · Cited by 142 · see citing works
The Clinical and Genetic Features of Huntington Disease
Sturrock, A., & Leavitt, B. R. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383573 · Cited by 142 · see citing works
Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative Disorders
Covarrubias‐Pinto, A., Acuña, A. I., Beltrán, F. A., Torres-Díaz, L., & Castro, M. A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226095 · Cited by 140 · see citing works
Ribeiro, M., Rosenstock, T. R., Oliveira, A. M., Oliveira, C. R., & Rego, A. C. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.023 · Cited by 139 · see citing works
Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases
Chaturvedi, R. K., & Beal, M. F. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.11.011 · Cited by 139 · see citing works
Self-citationCardiac dysfunction in the R6/2 mouse model of Huntington’s disease
Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A., & Hoyt, K. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.016 · Cited by 136 · see citing works
Chaturvedi, R. K., Calingasan, N. Y., Yang, L., Hennessey, T., Johri, A., & Beal, M. F. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq229 · Cited by 135 · see citing works
Self-citationRačkayová, V., Cudalbu, C., Pouwels, P. J. W., & Braissant, O. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.11.007 · Cited by 130 · see citing works
Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice
Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127 · see citing works
Self-citationModulation of nucleosome dynamics in Huntington's disease
Stack, E. C., Signore, S. J. D., Luthi‐Carter, R., Soh, B. Y., Goldstein, D. R., Matson, S. A., Goodrich, S., Markey, A., Cormier, K., Hagerty, S. W., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm064 · Cited by 119 · see citing works
Self-citationBürklen, T. S., Schlattner, U., Homayouni, R., Gough, K. M., Rak, M., Szeghalmi, A. V., & Wallimann, T. (2006) · BioMed Research International · doi:10.1155/jbb/2006/35936 · Cited by 119 · see citing works
Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers
Braissant, O. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9433-2 · Cited by 112 · see citing works
Creatine as a booster for human brain function. How might it work?
Rae, C. D., & Bröer, S. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.08.010 · Cited by 108 · see citing works
Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease
Beal, M. F. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70812-0 · Cited by 103 · see citing works
Self-citationThe CREST-E study of creatine for Huntington disease
Hersch, S. M., Schifitto, G., Oakes, D., Bredlau, A., Meyers, C. M., Nahin, R. L., Rosas, H. D., & For the Huntington Study Group CREST-E Investigators and Coordinators (2017) · Neurology · doi:10.1212/wnl.0000000000004209 · Cited by 102 · see citing works
Self-citationPRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D., Doros, G. D., Gevorkian, S., Malarick, K., Reuter, M., Coutu, J., Triggs, T. D., Wilkens, P. J., Matson, W. R., Salat, D. H., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000187 · Cited by 98 · see citing works
Self-citationTherapy development in Huntington disease: From current strategies to emerging opportunities
Dickey, A. S., & Spada, A. R. L. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38494 · Cited by 98 · see citing works
Creatine for neuroprotection in neurodegenerative disease: end of story?
Bender, A., & Klopstock, T. (2016) · Amino Acids · doi:10.1007/s00726-015-2165-0 · Cited by 96 · see citing works
“Heads Up” for Creatine Supplementation and its Potential Applications for Brain Health and Function
Candow, D. G., Forbes, S. C., Ostojić, S. M., Prokopidis, K., Stock, M. S., Harmon, K. K., & Faulkner, P. (2023) · Sports Medicine · doi:10.1007/s40279-023-01870-9 · Cited by 95 · see citing works
Nabuurs, C. I. H. C., Choe, C., Veltien, A. A., Kan, H. E., van Loon, L. J. C., Rodenburg, R. J., Matschke, J., Wieringa, B., Kemp, G. J., Isbrandt, D., et al. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2012.241760 · Cited by 95 · see citing works
Valencia, A., Sapp, E., Kimm, J. S., McClory, H., Reeves, P., Alexander, J. S., Ansong, K. A., Masso, N., Frosch, M. P., Kegel, K. B., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds516 · Cited by 93 · see citing works
RetractedA systematic review of the treatment studies in Huntington’s disease since 1990
Bonelli, R. M., & Hofmann, P. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.2.141 · Cited by 93 · see citing works
The application of NMR-based metabonomics in neurological disorders
Holmes, E. C., Tsang, T. M., & Tabrizi, S. J. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.05.004 · Cited by 92 · see citing works
Kaempferol protects against rat striatal degeneration induced by 3‐nitropropionic acid
Lagoa, R., López‐Sánchez, C., Samhan-Arias, A. K., Gañán, C., García‐Martínez, V., & Gutiérrez‐Merino, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06331.x · Cited by 91 · see citing works
The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?
Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101 · see citing works
Chen, C. (2011) · PubMed · Cited by 89 · see citing works
Pharmacologic approaches to the treatment of Huntington's disease
Venuto, C. S., McGarry, A. J., Ma, Q., & Kieburtz, K. D. (2011) · Movement Disorders · doi:10.1002/mds.23953 · Cited by 86 · see citing works
Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA
Guidi, C., Potenza, L., Sestili, P., Martinelli, C., Guescini, M., Stocchi, L., Zeppa, S. D., Polidori, E., Annibalini, G., & Stocchi, V. (2007) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2007.09.018 · Cited by 84 · see citing works
Lim, J. L., Wilhelmus, M. M. M., de Vries, H. E., Drukarch, B., Hoozemans, J. J. M., & van Horssen, J. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1338-z · Cited by 83 · see citing works
A review of creatine supplementation in age-related diseases: more than a supplement for athletes
Smith, R. N., Agharkar, A. S., & Gonzales, E. B. (2014) · F1000Research · doi:10.12688/f1000research.5218.1 · Cited by 82 · see citing works
Targeting mitochondrial dysfunction in neurodegenerative disease: Part II
Burchell, V., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun‐Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003730434 · Cited by 82 · see citing works
Ullah, H., Minno, A. D., Santarcangelo, C., Khan, H. Z., & Daglia, M. (2021) · Antioxidants · doi:10.3390/antiox10040546 · Cited by 81 · see citing works
Evers, M. M., Toonen, L. J. A., & van Roon‐Mom, W. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8596-2 · Cited by 81 · see citing works
Wallimann, T., Tokarska-Schlattner, M., Neumann, D., Epand, R. M., Epand, R. F., Andres, R. H., Widmer, H. R., Hornemann, T., Saks, V. A., Agarkova, I., et al. (2007) · Wiley eBooks · doi:10.1002/9783527621095.ch7 · Cited by 81 · see citing works
Huntington’s Disease Clinical Trials Corner: February 2018
Rodrigues, F. B., & Wild, E. J. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-189001 · Cited by 78 · see citing works
Ireland, Z., Dickinson, H., Snow, R. J., & Walker, D. W. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.10.790 · Cited by 78 · see citing works
Sawant, N. A., Morton, H., Kshirsagar, S., Reddy, A. P., & Reddy, P. H. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02556-x · Cited by 74 · see citing works
Yoon, S., Kim, J. E., Hwang, J., Kim, T.-S., Kang, H. J., Namgung, E., Ban, S., Oh, S., Yang, J., Renshaw, P. F., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.027 · Cited by 71 · see citing works
8OHdG as a marker for Huntington disease progression
Long, J. D., Matson, W. R., Juhl, A. R., Leavitt, B. R., & Paulsen, J. S. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.02.012 · Cited by 71 · see citing works
Self-citationMilestones in Huntington disease
Shoulson, I., & Young, A. B. (2011) · Movement Disorders · doi:10.1002/mds.23685 · Cited by 70 · see citing works
- Authors
- Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., Ulug, A. M., Beal, M. F., Matson, W., Bogdanov, M., Ebbel, E., Zaleta, A., Kaneko, Y., Jenkins, B., Hevelone, N., Zhang, H., Yu, H., Schoenfeld, D., Ferrante, R., & Rosas, H. D.
- Affiliations
- Harvard University (US)
- From the Departments of Neurology, (S.M.H., S.G., A.Z., N.H., H.Z., H.Y., H.D.R.) and Biostatistics (D.S.), MassGeneral Institute for Neurodegenerative Disease, MGH-NMR Center and Athinoula A. Martinos Center for Biomedical Imaging (A.Z., B.J., N.H., H.D.R.), Massachusetts General Hospital and Harvard Medical School, Charlestown, MA; Center for Parkinson's Disease and Other Movement Disorders (K.M., C.M.), Department of Neurology, Sergievsky Center and Taub Institute for Research on Alzheimer's...
- ORCID
- Venue
- Neurology
- Published
- 2006-01-24
- Volume
- 66
- Issue
- 2
- Pages
- 250-252
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2163827910
- Cited by
- 313
- References
- 10
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 13 · 2023: 10 · 2022: 11 · 2021: 14 · 2020: 6 · 2019: 8 · 2018: 12 · 2017: 8 · 2016: 14 · 2015: 13 · 2014: 21 · 2013: 20 · 2012: 22
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (NS042861, NS 35255, R01NS035255)
- National Center for Research Resources (M01RR001066, M01-RR01066, M01RR000645, M01 RR00645)
- National Center for Complementary and Integrative Health (AT00613)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Physiology › Biochemical effects in animals
- Keywords
- creatine, Huntington's disease, 8-hydroxy-2'-deoxyguanosine, oxidative DNA damage, drug safety and tolerability, neuroprotection
- MeSH terms
- 8-Hydroxy-2'-Deoxyguanosine, Adult, Biological Availability, Brain, Creatine, Deoxyguanosine, Double-Blind Method, Female, Humans, Huntington Disease, Male, Middle Aged, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
